Taipei Veterans General Hospital

Transitioning from "Disease-Centric" to "Person-Centered": Advancements in Aging Research, Medical Education, and International Collaboration from NYCU

Retrieved on: 
Wednesday, November 8, 2023
Knowledge, Conditional sentence, WHO, Faculty, United Kingdom, Ageing, National Center for Theoretical Sciences, Physics, Health status of Asian Americans, Medical school, Education, Physician, Welfare, Disability studies, National Yang Ming Chiao Tung University School of Law, Deficit spending, Research, Exercise, Dementia, Multimedia, Ministry, Rehabilitation, Growth, School, Ministry of Health and Welfare (South Korea), Curriculum, World Health Organization, Risk, Factorization of polynomials, Multimorbidity, NYCU, Student, TIGER, Taipei Veterans General Hospital, Video, Disability, Language, Anxiety, Patient, Hospital, Diagnosis, Communication, Sarcopenia, Nursing, Health, Geriatrics, Medicine

In such circumstances, relying solely on disease-centric approaches to assess their care needs would result in significant gaps in care planning.

Key Points: 
  • In such circumstances, relying solely on disease-centric approaches to assess their care needs would result in significant gaps in care planning.
  • Henceforth, there exists a pressing necessity for interdisciplinary collaboration and communication among diverse institutions in the foreseeable future.
  • However, the integration of knowledge and resources emerges as the pivotal approach to address the challenges posed by an aging society.
  • NYCU is the exclusive medical institution in Taiwan that mandates geriatrics as a required course in its program.

Taiwan's First Heavy Ion Therapy System Starts Treatment at Taipei Veterans General Hospital

Retrieved on: 
Thursday, May 18, 2023
Proton, Taipei Veterans General Hospital, Neoplasm, Particle therapy, Respiration, Cancer, Light, Quality of life, Carbon, Noetics, Nuclear Instruments and Methods in Physics Research, Motion, Hospital, Patient, Hybrid system, Medical imaging

TOKYO, May 18, 2023 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501) announced today that it has delivered a heavy ion therapy system to Taipei Veterans General Hospital and the system has started treatment as of May 15.

Key Points: 
  • TOKYO, May 18, 2023 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501) announced today that it has delivered a heavy ion therapy system to Taipei Veterans General Hospital and the system has started treatment as of May 15.
  • This marks the first operation of heavy ion therapy system in Taiwan and Hitachi's first heavy ion therapy system outside of Japan.
  • This system has been installed in the new Heavy Ion Therapy Center of Taipei Veterans General Hospital, consisting of two treatment rooms, each equipped with vertical and horizontal ports.
  • Recognized as an advanced type of cancer radiotherapy, this heavy ion therapy system is intended to address the unmet cancer treatment demand beyond the capacity of existing proton therapy systems in Taiwan.

Taichung Veterans General Hospital selects RayStation

Retrieved on: 
Friday, July 7, 2023
CBCT, Taipei Veterans General Hospital, MCO, Proton therapy, RaySearch Laboratories, Cancer, Radiation therapy, Patient, Hospital, Sumitomo Group, Sumitomo Corporation, Medical imaging, Q2

STOCKHOLM, July 7, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the proton therapy machine vendor Sumitomo Corporate has placed an order for RayStation®* treatment planning system to be installed at Taichung Veterans General Hospital (TVGH), Taichung, Taiwan.

Key Points: 
  • STOCKHOLM, July 7, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the proton therapy machine vendor Sumitomo Corporate has placed an order for RayStation®* treatment planning system to be installed at Taichung Veterans General Hospital (TVGH), Taichung, Taiwan.
  • TVGH will use a Sumitomo proton therapy machine with Sumitomo's compact next-generation system, to which RayStation will be adapted, enabling TVGH to utilize the new system's method for very fast delivery of treatment plans for the treatment of moving tumors.
  • Dr. Weir Chiang You, Chief of the Department of Radiation Oncology at Taipei Veterans General Hospital (TCVGH), says: "I am delighted to announce that TVGH will soon be incorporating the state-of-the-art Sumitomo proton therapy machine into our clinical practice.
  • Their premier product, RayStation, will provide our medical professionals with the tools they need to optimize patient treatment plans and improve therapy outcomes."

NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO's Demo Day

Retrieved on: 
Wednesday, June 7, 2023
Science, technology, engineering, and mathematics, Exhibition, Demo, National Science and Technology Council (Taiwan), Taipei Veterans General Hospital, Taipei Medical University Hospital, Biotechnology, 3D, University, Y, Insteon, Multimedia, Attention, Antibody, Immunotherapy, CDMO, LabCentral, Medicine, Hospital, Ecosystem, NSTC, Video game, Science

The event effectively assisted start-up teams in establishing global exposure and promoting cooperation and exchange between Taiwan's biotech industry and the global market.

Key Points: 
  • The event effectively assisted start-up teams in establishing global exposure and promoting cooperation and exchange between Taiwan's biotech industry and the global market.
  • The Demo Day was held in the form of Demo & Pitch, featuring presentations by 20 teams supported by NSTC.
  • Among them, Taipei Veterans General Hospital, China Medical University Hospital and Show Chwan Memorial Hospital are the teams of NSTC's Smart Healthcare Industry-Academia Consortium Project.
  • JelloX Biotech has developed patented 3D pathology tissue processing and imaging technology to develop next-generation pathology detection technology.

Neuboron Medical Group and Xiamen Humanity Hospital Make ‘Grand Debut’ at Xiamen BNCT Tech Forum to Drive Clinical Application and New Drug Development

Retrieved on: 
Tuesday, May 9, 2023
Research, Medical Devices, Neurology, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Neutron, Pharmacy, Drug development, GBM, NCT, Peking Union Medical College Hospital, Taipei Veterans General Hospital, China Pharmaceutical University, Sichuan University, Dalian University of Technology, Head, NMG, Toxicity, National Changhua University of Education, Glioblastoma, Nuclear medicine, Patient, BNCT, BPA, Molecular imaging, Shenyang Pharmaceutical University, Accelerator, Hospital, Nanjing University, Tamkang University, Safety, Pharmaceutical industry

The event agenda underscored various topics, including BNCT clinical research, molecular imaging, nuclear medicine, and the development of next-generation boron drugs.

Key Points: 
  • The event agenda underscored various topics, including BNCT clinical research, molecular imaging, nuclear medicine, and the development of next-generation boron drugs.
  • The conference was a hybrid event bringing together around 5,000 physical and virtual attendees to discuss the outlooking of BNCT's new drug and clinical development.
  • In addition, Prof. Dr. Yuan-Hao Liu of NMG presented the latest clinical research findings from the Xiamen BNCT center.
  • The Xiamen BNCT center strives to promote open innovation within the global BNCT community to accelerate the clinical application of BNCT research and novel drug development from bench to market in the short future.

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, January 5, 2023
Taipei Veterans General Hospital, Report, Grifola, Breast cancer, Metastasis, CNS, US, MSKCC, Ophthalmology, US Foods, Safety, FDA, IND, Data, Memorial Sloan Kettering Cancer Center, Microdeletion syndrome, Efficacy, MDS, NSCLC, Grifola frondosa, Pharmaceutical industry, Patient

FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology today announced that the US Food & Drug Administration notified the company that the IND application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519, for advanced inoperable or metastatic EGFR-mutated non-small cell lung cancer has been approved and the study can proceed.

Key Points: 
  • FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology today announced that the US Food & Drug Administration notified the company that the IND application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519, for advanced inoperable or metastatic EGFR-mutated non-small cell lung cancer has been approved and the study can proceed.
  • The treatment, which is being co-developed by BioKey, Inc., a wholly owned subsidiary of ABVC based in Fremont, California and by the Rgene Corporation was submitted to the FDA by Rgene on November 30, 2022.
  • The application, designated IND 161602, was approved on December 30, 2022.
  • “We are pleased the US FDA approved IND 161602 within the 30-day review period.

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

Retrieved on: 
Wednesday, February 2, 2022
CNS, Medical Center, Principal, Part, Forward-looking statement, ADHD, Patient, NASDAQ, University, University of California, San Francisco, Trial of the century, SEC, UCSF, Distribution, Cedars-Sinai Medical Center, Technology, US, Part Two, Attention deficit hyperactivity disorder, Population, CAGR, Hospital, Stimulant, Taipei Veterans General Hospital, U.S. Securities and Exchange Commission, Demography, Company, Risk, Stanford University, GLOBE, ITT, Ophthalmology, Phase, Drug development, San Francisco, Comment, National Taiwan University Hospital, Security (finance), CA, Pharmaceutical industry, Adult

Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022.

Key Points: 
  • Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022.
  • This randomized, double-blind, placebo-controlled Part 2 study involves a total of approximately 100 patients from the United States and Taiwan.
  • The results from the Part 1 study demonstrated the therapeutic value of PDC-1421 and support further clinical development of ABV-1505 for the treatment of ADHD.
  • We expect to have a productive discussion finalizing the Part 2 study protocol on February 14th, said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma.

A Stitch in Time: Taiwan and Japan Join Hands in Providing Critical Care

Retrieved on: 
Thursday, November 25, 2021
Surgery, Infectious Diseases, Hospitals, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Oncology, Neutron, Patient, Time, Recurrence, Cancer, Rhabdomyosarcoma, BNCT, COVID-19, Taipei Veterans General Hospital, Welfare, Neoplasm, Brain, Malignant peripheral nerve sheath tumor, Cyberknife, THOR, Hospital, Multimedia, Medical imaging

Japan has donated five batches of the AZ COVID-19 vaccine to Taiwan, and Taiwan has reciprocated by providing treatment at NTHUs Boron Neutron Capture Therapy Center (BNCTC) for a 20-year-old Japanese woman suffering from a malignant brain tumor.

Key Points: 
  • Japan has donated five batches of the AZ COVID-19 vaccine to Taiwan, and Taiwan has reciprocated by providing treatment at NTHUs Boron Neutron Capture Therapy Center (BNCTC) for a 20-year-old Japanese woman suffering from a malignant brain tumor.
  • (Photo: National Tsing Hua University)
    The doctor in charge of the treatment was Yi-Wei Chen of the Oncology Department at Taipei Veterans General Hospital (TVGH).
  • He said that only Taiwan and Japan have medical centers using boron neutron capture therapy (BNCT) to treat cancer.
  • Chen said that the Japanese patient was originally diagnosed with rhabdomyosarcoma of the right ear canal at the age of six.

The Synergy Between AI and Healthcare Explored at 2021 Taiwan Innotech Expo

Retrieved on: 
Tuesday, October 19, 2021
National Taiwan University Hospital, Wilson, AstraZeneca, AWS, Graphics processing unit, Privacy, Area studies, Association, Technology, Hospital, COVID-19, Collection, Precision medicine, Drug development, Genomics, Ministry of Science, Amazon Web Services, Amazon, Ministry, Taipei Veterans General Hospital, Industry, AI, Ministry of Health and Welfare (South Korea), Cancer, Deep learning, Academia Sinica, MRI, Medical device

However, it requires a high degree of integration among various previously unrelated sectors to ensure competence.

Key Points: 
  • However, it requires a high degree of integration among various previously unrelated sectors to ensure competence.
  • According to Wu, it is necessary to find talents with interdisciplinary skills and to overcome the differences in organizational cultures.
  • Wilson To, the head of worldwide healthcare, life sciences and genomics at Amazon Web Services (AWS), also participated in the Expo, and shared Amazon's experiences in smart healthcare.
  • At the Innotech Expo, Nvidia's global head of medical AI, Mona Flores, indicated that Nvidia had leveraged deep learning to come up with customized data processing and analytics for medical AI applications.

2021 Taiwan Innotech Expo focuses on the tech highlights of six key sectors

Retrieved on: 
Thursday, October 14, 2021
Taipei Veterans General Hospital, Industry, Solution, IOT, NASA, Czech, MOST, Academia Sinica, AI, TIE, Area studies, Conditional sentence, List, CEO, Education, Federal Ministry of Science and Technology, Electronics, Ministry of Health and Welfare (South Korea), Ministry, Medical device

TAIPEI, Taiwan, Oct. 14, 2021 /PRNewswire/--The post-pandemic world is entering a period characterized by restructuring and consolidation.

Key Points: 
  • TAIPEI, Taiwan, Oct. 14, 2021 /PRNewswire/--The post-pandemic world is entering a period characterized by restructuring and consolidation.
  • The event invited multiple CEOs from well-established businesses to share online their unique standpoints on innovation and market opportunities from an industry perspective.
  • A number of leading medical institutions are utilizing advanced technologies to enhance their smart healthcare and smart hospital services.
  • In the Future Tech Theme Pavilion (FUTEX), top international business executives as well as academic experts were invited to speak from global perspectives.